Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis.

Nature medicine - 1 Oct 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Genes, ras
Share to Mutation
Share to Pancreatic Neoplasms
Share to Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36207523
DOI: 10.1038/s41591-022-02008-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis.PMID 36207523Read ↗

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Semantic proximity Read ↗

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Semantic proximity Read ↗

State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.Semantic proximity Read ↗

Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.Semantic proximity Read ↗

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant TumorsSemantic proximity Read ↗

Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors.Semantic proximity Read ↗

"Undruggable KRAS": druggable after all.Semantic proximity Read ↗

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.Semantic proximity Read ↗

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.Semantic proximity Read ↗

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.